ambrisentan

an ET(A) receptor antagonist and antihypertensive agent; studied for use in pulmonary arterial hypertension

Also Known As:

(+)-(2S)-2-((4,6-dimethylpyrimidin-2-yl)oxy)-3-methoxy-3,3-diphenylpropanoic acid; (+)-ambrisentan; (+-)-ambrisentan; (-)-ambrisentan; (R)-ambrisentan; (S)-ambrisentan; BSF 208075; BSF-208075; BSF208075; GSK 1325760; GSK 1325760A; GSK-1325760; GSK-1325760A; GSK1325760; GSK1325760A; LU 208075; LU-208075; LU208075; Letairis; Volibris; ambrisentan, (+-)-; ambrisentan, (-)-; ambrisentan, (R)-

Networked: 230 relevant articles (33 outcomes, 61 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Rubin, Lewis J: 14 articles (12/2019 - 07/2005)
2.	Blair, Christiana: 12 articles (01/2020 - 11/2012)
3.	Oudiz, Ronald J: 10 articles (12/2019 - 06/2008)
4.	Dufton, Christopher: 10 articles (12/2012 - 07/2005)
5.	Langley, Jonathan: 9 articles (01/2020 - 08/2015)
6.	Frost, Adaani E: 9 articles (12/2019 - 08/2005)
7.	Hoeper, Marius M: 9 articles (12/2019 - 09/2006)
8.	McLaughlin, Vallerie V: 9 articles (12/2019 - 06/2008)
9.	Gillies, Hunter: 9 articles (07/2017 - 07/2012)
10.	Peacock, Andrew J: 7 articles (12/2019 - 01/2015)

Related Diseases

1.	Pulmonary Arterial Hypertension 05/01/2024 - "This open-label, extension study assessed long-term safety, tolerability, and efficacy of ambrisentan in a pediatric population (age 8- < 18 years) with pulmonary arterial hypertension (PAH). Following completion of a 6-month, randomized study, participants entered the long-term extension at individualized ambrisentan dosages (2.5/5/7.5 or 10 mg/day). " 01/01/2020 - "A Randomized Study of Safety and Efficacy of Two Doses of Ambrisentan to Treat Pulmonary Arterial Hypertension in Pediatric Patients Aged 8 Years up to 18 Years." 11/17/2009 - "This study evaluated the safety and efficacy of ambrisentan for a period of 2 years in patients with pulmonary arterial hypertension (PAH). " 06/01/2012 - "To investigate the safety and efficacy of long-term administration of ambrisentan in Japanese adults with pulmonary arterial hypertension (PAH). " 06/01/2012 - "Long-term safety and efficacy of ambrisentan in Japanese adults with pulmonary arterial hypertension."
2.	Dyspnea (Shortness of Breath) 08/01/2011 - "In ARIES-E, a 2-year extension of ARIES-1 and -2, approved dosages of ambrisentan (5 and 10 mg/day) were associated with a sustained improvement in 6MWD, a generally sustained improvement in dyspnea, and a low risk of clinical worsening and of death. " 01/01/2007 - "In Phase 3 clinical trials in patients with PAH, ambrisentan (2.5-10 mg orally once-daily) improved exercise capacity, Borg dyspnea index, time to clinical worsening, WHO functional class, and quality of life compared with placebo. " 07/01/2005 - "In a Phase II study, ambrisentan improved 6-minute walk distance, Borg dyspnea index, World Health Organization Functional Class, and hemodynamics. " 08/01/2011 - "A decrease in dyspnea and a delay in clinical worsening were among the improvements in secondary outcomes generally observed with ambrisentan versus placebo. " 08/01/2011 - "Six months' treatment with ambrisentan 5 mg/day significantly improved 6MWD (primary outcome measure) and dyspnea relative to baseline in an open-label, non-comparative, multicenter study in a diverse population of patients with PAH or non-PAH forms of pulmonary hypertension (ARIES-3 [n = 224]). "
3.	Pulmonary Hypertension 03/01/2024 - "A longitudinal descriptive study on the prescription patterns of ambrisentan in patients with pulmonary hypertension (all the groups) was conducted between January 2021 and December 2022 based on a population database of members of the Colombian Health System. " 04/01/2019 - "This multicenter, randomized, double-blind, placebo-controlled study assessed ambrisentan or placebo in patients with inoperable chronic thromboembolic pulmonary hypertension. " 04/01/2017 - "Open label study of ambrisentan in patients with exercise pulmonary hypertension." 01/05/2024 - "Provision of ambrisentan from a health-system specialty pharmacy affiliated with a pulmonary hypertension Center of Comprehensive Care." 04/01/2019 - "Ambrisentan for treatment of inoperable chronic thromboembolic pulmonary hypertension (CTEPH)."
4.	Systemic Scleroderma (Systemic Sclerosis) 10/26/2019 - "Early treatment with ambrisentan of mildly elevated mean pulmonary arterial pressure associated with systemic sclerosis: a randomized, controlled, double-blind, parallel group study (EDITA study)." 01/01/2016 - "Effect of ambrisentan on peripheral circulation in patients with systemic sclerosis." 12/01/2012 - "The purpose of this pilot study was to describe the changes in hemodynamics and exercise capacity in patients with systemic sclerosis (SSc) spectrum-associated ePH treated with open-label daily ambrisentan. " 03/05/2015 - "Evaluation of the effect of ambrisentan on digital microvascular flow in patients with systemic sclerosis using laser Doppler perfusion imaging: a 12-week randomized double-blind placebo controlled trial." 06/01/2013 - "Efficacy of ambrisentan in the treatment of digital ulcers in patients with systemic sclerosis: a preliminary study."
5.	Hypertension (High Blood Pressure) 09/01/2011 - "No data have been published on the efficacy of ambrisentan on improvement of exercise capacity in patients with portopulmonary hypertension (PoPH). " 01/01/2011 - "Safety and efficacy of ambrisentan for the treatment of portopulmonary hypertension." 01/01/2020 - "Ambrisentan in portopulmonary hypertension: A multicenter, open-label trial." 09/01/2011 - "Ambrisentan improves exercise capacity and symptoms in patients with portopulmonary hypertension." 01/01/2011 - "We describe hemodynamic responses and clinical outcomes of patients with portopulmonary hypertension (POPH) treated with ambrisentan. "

Related Drugs and Biologics

1.	Tadalafil (Cialis)
2.	Bosentan (Tracleer)
3.	Sildenafil Citrate (Viagra)
4.	Endothelin Receptor Antagonists
5.	macitentan
6.	ambrisentan
7.	Endothelin Receptors (Endothelin Receptor)
8.	Oxygen (Dioxygen)
9.	Endothelins (Endothelin)
10.	Endothelin A Receptor

Related Therapies and Procedures

1.	Therapeutics
2.	Lasers (Laser)
3.	Oral Administration
4.	Warm Ischemia
5.	Organ Transplantation